Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors

Wednesday, November 26, 2008 General News
Email Print This Page Comment
Font : A-A+

MIAMI, Nov. 26 Thomas K. Equels, President and ManagingDirector of the Equels Law Firm, has been elected to the board of directorsfor Hemispherx BioPharma, Inc. (Amex: HEB), a Philadelphia-basedbiopharmaceutical company engaged in the manufacture and clinical developmentof new drug entities for the treatment of viral and immune-based disorders.

Equels' legal practice is devoted to litigation, with particular emphasison civil racketeering, business torts and commercial matters. Prior to hisboard election, Equels served as Hemispherx BioPharma's litigation counsel.

For more than 25 years, Equels has represented national and stategovernments, and companies in the banking, insurance, aviation,pharmaceutical, construction and development industries. He has extensiveexperience in complex litigation matters including:

Equels earned a law degree with high honors from the Florida StateUniversity School of Law and earned a bachelor of arts degree, summa cumlaude, from Troy State University. He is a member of The Florida BarAssociation, the American Bar Association and the Academy of Florida TrialLawyers.

About the Equels Law Firm

The Equels Law Firm has established itself as one of Florida's mosteffective and experienced law firms in the areas of complex litigation,government, business torts and personal injury law. The Equels Law Firmattorneys in Miami, Orlando and Tallahassee are known for providinghigh-quality, timely, efficient and personalized service to its local,national and international clients, whether representing them in eitherfederal and state court or before federal, state or local governments. You canlearn more about the Equels Law Firm at www.equelslaw.com or by calling ThomasEquels at (305) 859-7700.

About Hemispherx BioPharma

Hemispherx BioPharma, Inc. is a specialty pharma company engaged in themanufacture and clinical development of new drug entities for treatment ofseriously debilitating disorders. Hemispherx's flagship products includeAlferon N Injection(R) (FDA approved for a category of sexually transmitteddiseases) and the experimental therapeutics, Ampligen(R) and Oragens.Ampligen(R) and Oragens represent experimental RNA nucleic acids beingdeveloped for globally important debilitating diseases and disorders of theimmune system. Hemispherx's platform technology includes large and small agentcomponents for potential treatment of various severely debilitating and lifethreatening diseases. Hemispherx has in excess of 50 issued patents comprisingits core intellectual property estate and a fully commercialized product(Alferon N Injection(R)). The Company wholly owns and exclusively operates aGMP certified manufacturing facility in the United States for commercialproducts. For more information please visit www.hemispherx.net.-- Obtained a $26.8 million judgment in 2008 in a breach of contract action against Bear Stearns, for the Delaware Insurance Commissioner, related to an insolvent insurance company. -- Obtained a $15 million judgment in 2005 against boy band guru Lou Pearlman of Trans Continental Records, Inc. -- Obtained a $44 million judgment against Manuel Noriega for public money he misappropriated from the Republic of Panama. -- Recovered more than $100 million misappropriated and money laundered overseas by former insiders of a now defunct insurance company being liquidated by the State of Delaware's Insurance Commissioner. -- Obtained and collected a $10.6 million judgment against the FDIC for breach of contract involving a client's purchase of a national mortgage company owned by a failed savings and loan. -- Prosecuted a bank fraud claim against an international lender, which resulted in a jury awarding $2.6 million damages for fraud and an order invalidating a $9 million mortgage.

SOURCE Equels Law Firm


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook